Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | EIF4E | P06730 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | TOP1 | P11387 | 1/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.71 |
| ▸ | THPO | P40225 | 1/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.71 |
| ▸ | PNP | P00491 | 3/20 | 0.64 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27568953 | 1.00 | LMNA (0.71) | LMNASMN1; SMN2ALDH1A1TSHRGLA | |
| SCHEMBL27568954 | 1.00 | LMNA (0.71) | LMNASMN1; SMN2ALDH1A1TSHRGLA | |
| SCHEMBL23479943 | 0.89 | LMNA (0.57) | LMNASMN1; SMN2ALDH1A1TSHRGLA | |
| SCHEMBL13320671 | 0.86 | LMNA (0.76) | LMNASMN1; SMN2ALDH1A1TSHRGLA | |
| SCHEMBL12901991 | 0.86 | LMNA (0.76) | LMNASMN1; SMN2ALDH1A1TSHRGLA | |
| SCHEMBL2845582 | 0.86 | LMNA (0.76) | LMNASMN1; SMN2ALDH1A1TSHRGLA | |
| SCHEMBL13320541 | 0.86 | LMNA (0.76) | LMNASMN1; SMN2ALDH1A1TSHRGLA | |
| SCHEMBL13352082 | 0.86 | LMNA (0.76) | LMNASMN1; SMN2ALDH1A1TSHRGLA | |
| SCHEMBL1200223 | 0.85 | PNP (0.71) | LMNASMN1; SMN2ALDH1A1TSHRGLA | |
| SCHEMBL12892516 | 0.85 | PNP (0.71) | LMNASMN1; SMN2ALDH1A1TSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230235330-A1 | CONJUGATE OF DOUBLE-STRANDED SIRNA ANALOGUE | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230235330-A1 | CONJUGATE OF DOUBLE-STRANDED SIRNA ANALOGUE | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230220386-A1 | SIRNA CONJUGATE, DOUBLE-STRANDED SIRNA CONJUGATE, SALT THEREOF AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230220386-A1 | SIRNA CONJUGATE, DOUBLE-STRANDED SIRNA CONJUGATE, SALT THEREOF AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20100129317-A1 | AZOLE NUCLEOSIDES AND USE AS INHIBITORS OF RNA AND DNA VIRAL POLYMERASES | SOUTHERN RESEARCH INSTITUTE (US) | 2010-05-27 | — | — | US | disclosed |
| CN-1255421-C | Process for preparation of L-ribavirin | CLARIANT LSM ITALIA SPA (IT) | 2006-05-10 | — | — | CN | disclosed |
| EP-1485396-A2 | NUCLEOSIDE 5'-MONOPHOSPHATE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| CN-1535278-A | Process for preparation of L-ribavirin | �����ﰲ�ط���������ѧ(�����)�ɷ��� | 2004-10-06 | — | — | CN | disclosed |
| US-20040023901-A1 | Nucleoside 5'-monophosphate mimics and their prodrugs | BIOTA HOLDINGS LIMITED (AU) | 2004-02-05 | — | — | US | disclosed |
| WO-2003073989-A2 | NUCLEOSIDE 5'-MONOPHOSPHATE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| US-RE29835-E | PHARMACEUTICAL | ICN PHARMACEUTICALS (US) | 1978-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220386-A1 | SIRNA CONJUGATE, DOUBLE-STRANDED SIRNA CONJUGATE, SALT THEREOF AND APPLICATION THEREOF | HAVCR2, SNRPE, SCARB1 | LMNA 3104/4885SMN1; SMN2 2890/4885ALDH1A1 1780/4885 |
| US-20040023901-A1 | Nucleoside 5'-monophosphate mimics and their prodrugs | MTAP, ENTPD5, PNP | LMNA 4394/4885SMN1; SMN2 2624/4885ALDH1A1 2159/4885 |
| US-20230235330-A1 | CONJUGATE OF DOUBLE-STRANDED SIRNA ANALOGUE | HAVCR2, EIF2AK2, ASGR1 | LMNA 1373/4885SMN1; SMN2 4200/4885ALDH1A1 3942/4885 |
| US-20100129317-A1 | AZOLE NUCLEOSIDES AND USE AS INHIBITORS OF RNA AND DNA VIRAL POLYMERASES | RNASEH1, RNASEL, POLR2E | LMNA 739/4885SMN1; SMN2 3616/4885ALDH1A1 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.